Latest news and press releases about COMPASS Pathways plc (CMPS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder.
Price
| Price | $13.80 |
| Market Cap | $1.9B |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | 16.38 |
| EV / EBITDA | -3.93 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -398.21% |
| Return on Invested Capital | -129.74% |
| Return on Assets | -78.12% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AVNS · CYH · EHAB · FDMT · GOSS · KALV · PRTA
Explore sector: Healthcare · Biotechnology
More sections of CMPS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks